 Connection
Nathan Dahl to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications Nathan Dahl has written about Xenograft Model Antitumor Assays.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.439 |
|
|
|
-
Sobral LM, Walker FM, Madhavan K, Janko E, Donthula S, Danis E, Bompada P, Balakrishnan I, Wang D, Pierce A, Haag MM, Carstens BJ, Serkova NJ, Foreman NK, Venkataraman S, Veo B, Vibhakar R, Dahl NA. Targeting processive transcription for Myc-driven circuitry in medulloblastoma. Neuro Oncol. 2025 Oct 01; 27(10):2697-2710.
Score: 0.182
-
Walker FM, Sobral LM, Danis E, Sanford B, Donthula S, Balakrishnan I, Wang D, Pierce A, Karam SD, Kargar S, Serkova NJ, Foreman NK, Venkataraman S, Dowell R, Vibhakar R, Dahl NA. Rapid P-TEFb-dependent transcriptional reorganization underpins the glioma adaptive response to radiotherapy. Nat Commun. 2024 May 30; 15(1):4616.
Score: 0.166
-
Wang D, Ritz C, Luo Y, Suresh A, Pierce A, Veo B, Brunt B, Dahl N, Serkova N, Venkataraman S, Danis E, Kus K, Mazan M, Rzymski T, Vibhakar R. Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma. Nat Commun. 2025 Dec 16; 16(1):11152.
Score: 0.046
-
Balakrishnan I, Madhavan K, Pierce A, Michlin J, Brunt B, Lakshmanachetty S, Wang D, DeSisto J, Nuss ZJ, Davidson N, Walker F, Suresh A, Donson A, Sanford B, Jones KL, Danis EP, Mitra SS, Green AL, Dahl N, Vibhakar R, Venkataraman S. Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma. Cancer Res. 2025 08 15; 85(16):3089-3110.
Score: 0.045
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|